Haleon plc 6-K, filed Jul 7, 2025
Haleon plc (HLN)
6-K
2025-07-07
For: 2025-07-07
View Original
Added on
April 05, 2026
About this 6-K
Haleon plc filed this 6-K on July 7, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
07 July
2025 - “Historic Proforma Category Financial
Performance”
|
99.1
Haleon plc: Historic Proforma Category Financial
Performance
7 July
2025: Haleon
plc (the "Company" or "Haleon") today releases the historical
proforma category financial information, aligned with the
announcement at the Capital Markets Day on 1 May 2025. Haleon will
now be reporting six categories: Oral Health; Vitamins, Minerals,
and Supplements (VMS); Pain Relief; Respiratory Health; Digestive
Health; and Therapeutic Skin Health and Other.
Compared
to previous reporting, the new structure:
|
●
|
Splits out Digestive Health & Other into Digestive Health, and
Therapeutic Skin Health and Other
|
|
●
|
Smokers Health which had previously been reported as part of
Digestive Health and Other will now be included in Respiratory
Health
|
|
●
|
There are no changes to other categories not outlined
above
|
We will begin reporting in this
new category structure at our 2025 Half Year Results on 31 July
2025. The
purpose of this change is to better align Haleon's reporting with
the strategic opportunities ahead as well as improve visibility of
Haleon's financial performance. Haleon's geographical split remains
unchanged.
Detailed
below is the quarterly pro-forma actual and comparative financial
information on this basis. Definitions for non-IFRS measures can be
found on pages 19-27 in Haleon's 2024 Full Year Results, and pages
43-50 in Haleon's Annual Report and Form 20-F 2024.
|
Restated FY 2023 and FY 2024 reported revenue, organic revenue
growth, and reported revenue growth by category
(unaudited)
|
|||||||
|
|
2023
|
|
2024
|
||||
|
|
£m revenue
|
Organic Revenue Growth
|
Reported Revenue Growth
|
|
£m revenue
|
Organic Revenue Growth
|
Reported Revenue Growth
|
|
Oral Health
|
3,136
|
10.6%
|
6.1%
|
|
3,312
|
9.6%
|
5.6%
|
|
VMS
|
1,640
|
0.9%
|
-2.1%
|
|
1,696
|
7.6%
|
3.4%
|
|
Pain Relief
|
2,652
|
7.4%
|
4.0%
|
|
2,564
|
0.1%
|
-3.3%
|
|
Respiratory Health
|
2,244
|
11.7%
|
8.2%
|
|
2,122
|
1.0%
|
-5.4%
|
|
Digestive Health
|
1,012
|
5.8%
|
1.9%
|
|
1,029
|
5.5%
|
1.7%
|
|
Therapeutic Skin Health and Other
|
618
|
8.8%
|
1.5%
|
|
510
|
9.8%
|
-17.5%
|
|
TOTAL
|
11,302
|
8.0%
|
4.1%
|
|
11,233
|
5.0%
|
-0.6%
|
|
Restated quarterly reported revenue by category
(unaudited)
|
|
|
|
|
|
|
|
|
|||||
|
|
2023
|
|
2024
|
|
2025
|
||||||||
|
£m
|
Q1
|
Q2
|
Q3
|
Q4
|
FY
|
|
Q1
|
Q2
|
Q3
|
Q4
|
FY
|
|
Q1
|
|
Oral Health
|
811
|
778
|
790
|
757
|
3,136
|
|
854
|
829
|
810
|
819
|
3,312
|
|
880
|
|
VMS
|
405
|
411
|
410
|
414
|
1,640
|
|
422
|
435
|
407
|
432
|
1,696
|
|
416
|
|
Pain Relief
|
724
|
681
|
636
|
611
|
2,652
|
|
662
|
641
|
628
|
633
|
2,564
|
|
661
|
|
Respiratory Health
|
638
|
455
|
563
|
588
|
2,244
|
|
590
|
454
|
581
|
497
|
2,122
|
|
525
|
|
Digestive Health
|
259
|
256
|
234
|
263
|
1,012
|
|
256
|
264
|
239
|
270
|
1,029
|
|
254
|
|
Therapeutic Skin Health and Other
|
149
|
171
|
165
|
133
|
618
|
|
135
|
152
|
115
|
108
|
510
|
|
117
|
|
TOTAL
|
2,986
|
2,752
|
2,798
|
2,766
|
11,302
|
|
2,919
|
2,775
|
2,780
|
2,759
|
11,233
|
|
2,853
|
|
Restated quarterly organic revenue growth by category
(unaudited)
|
|
|
|
||||||
|
|
2023
|
|
2024
|
|
2025
|
||||
|
%
|
FY
|
|
Q1
|
Q2
|
Q3
|
Q4
|
FY
|
|
Q1
|
|
Oral Health
|
10.6%
|
|
10.6%
|
9.1%
|
8.2%
|
10.6%
|
9.6%
|
|
6.6%
|
|
VMS
|
0.9%
|
|
9.9%
|
8.5%
|
3.7%
|
8.2%
|
7.6%
|
|
0.9%
|
|
Pain Relief
|
7.4%
|
|
-4.8%
|
-4.0%
|
3.1%
|
7.4%
|
0.1%
|
|
2.6%
|
|
Respiratory Health
|
11.7%
|
|
-2.7%
|
1.3%
|
8.2%
|
-2.6%
|
1.0%
|
|
0.7%
|
|
Digestive Health
|
5.8%
|
|
2.2%
|
5.2%
|
9.0%
|
5.8%
|
5.5%
|
|
2.3%
|
|
Therapeutic Skin Health and Other
|
8.8%
|
|
7.4%
|
10.7%
|
0.7%
|
24.2%
|
9.8%
|
|
10.4%
|
|
TOTAL
|
8.0%
|
|
3.0%
|
4.1%
|
6.1%
|
6.8%
|
5.0%
|
|
3.5%
|
|
Restated quarterly reported revenue growth by category
(unaudited)
|
|
|
|
|
|||||
|
|
2023
|
|
2024
|
|
2025
|
||||
|
%
|
FY
|
|
Q1
|
Q2
|
Q3
|
Q4
|
FY
|
|
Q1
|
|
Oral Health
|
6.1%
|
|
5.3%
|
6.6%
|
2.5%
|
8.2%
|
5.6%
|
|
3.0%
|
|
VMS
|
-2.1%
|
|
4.2%
|
5.8%
|
-0.7%
|
4.3%
|
3.4%
|
|
-1.4%
|
|
Pain Relief
|
4.0%
|
|
-8.6%
|
-5.9%
|
-1.3%
|
3.6%
|
-3.3%
|
|
-0.2%
|
|
Respiratory Health
|
8.2%
|
|
-7.5%
|
-0.2%
|
3.2%
|
-15.5%
|
-5.4%
|
|
-11.0%
|
|
Digestive Health
|
1.9%
|
|
-1.2%
|
3.1%
|
2.1%
|
2.7%
|
1.7%
|
|
-0.8%
|
|
Therapeutic Skin Health and Other
|
1.5%
|
|
-9.4%
|
-11.1%
|
-30.3%
|
-18.8%
|
-17.5%
|
|
-13.3%
|
|
TOTAL
|
4.1%
|
|
-2.2%
|
0.8%
|
-0.6%
|
-0.3%
|
-0.6%
|
|
-2.3%
|
Enquiries
|
Investors
|
Media
|
||
|
Jo Russell
|
+44 7787 392441
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Victoria Durman
|
+44 7894 505730
|
|
Emma White
|
+44 7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in
consumer health, with a purpose to deliver better everyday health
with humanity. Haleon's product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Its long-standing brands - such
as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne,
Theraflu and Voltaren - are built on trusted science, innovation
and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
July 07, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|